Evidence map›Paper›PMID 42256585›Full record

ArticleDiabetology international2026

Long-term efficacy and safety of sensor-augmented pump for type 1 diabetes.

Satoshi Takagi, Junnosuke Miura, Mikako Takita, Shota Mochizuki, Kanako Shimura, Sari Hoshina, Hiroko Takaike, Tetsuya Babazono

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Satoshi TakagiDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan.
Junnosuke MiuraDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan.ORCID 0000-0002-5115-1111
Mikako TakitaDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan.
Shota MochizukiDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan.
Kanako ShimuraDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan.
Sari HoshinaDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan.
Hiroko TakaikeDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan.
Tetsuya BabazonoDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims/introduction: To evaluate the real-world efficacy of sensor-augmented pump (SAP) for long-term glycemic control and glycemic variability indices. Materials and methods: This was a single-center, retrospective, observational study that included individuals with type 1 diabetes who switched from multiple daily injections to SAP or continuous subcutaneous insulin infusion (CSII). Changes in HbA1c and body weight up to 3 years were compared between the two groups. Changes in the proportion of participants in each group were also analyzed. In the SAP group, changes in continuous glucose monitoring (CGM) metrics were also examined. Results: There were 32 individuals in the SAP group and 39 in the CSII group. HbA1c decreased significantly in both groups at 1 year compared with the pre-introduction levels and was maintained for 3 years (- 0.83 ± 0.26%, Conclusions: In individuals who started SAP or CSII, HbA1c decreased after 1 year and was maintained for 3 years. Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-026-00908-3.

Indexed as

Continuous glucose monitoringGlycemic controlInsulin infusion systemsSensor-augmented pumpType 1 diabetes

Identifiers

PMID42256585
PMCPMC13237315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.